Amid the COVID-19 crisis, the United States Continuous Glucose Monitoring (CGM) was valued at $2,830 Million in 2021 and is expected to grow at a CAGR of 11.5% in the forecast period, to reach $6,000
| Founded year: | Not set |
| Funding rounds: | Not set |
| Total funding amount: | Not set |